靶向PRMT1可降低EGFR和KRAS突变型肺癌的癌症持续性和肿瘤复发率。
Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer.
作者信息
Sun Xiaoxiao, Kumbier Karl, Gayathri Savitha, Steri Veronica, Wu Lani F, Altschuler Steven J
机构信息
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
出版信息
Cancer Res Commun. 2025 Jan 1;5(1):119-127. doi: 10.1158/2767-9764.CRC-24-0389.
Abstract
Eliminating "persisters" before relapse is crucial for achieving durable treatment efficacy. This study provides a rationale for developing PRMT1-selective inhibitors to target cancer persisters and achieve more durable outcomes in oncogene-targeting therapies.
摘要
在复发前清除“持久性细胞”对于实现持久的治疗效果至关重要。本研究为开发PRMT1选择性抑制剂以靶向癌症持久性细胞并在靶向癌基因疗法中实现更持久的疗效提供了理论依据。
Zotero 插件